UNSPSC 51352421: Ethinyl estradiol and ethynodiol diacetate combination

This classification denotes a combination contraceptive drug. The first component of this drug is ethinyl estradiol, a therapeutic estradiol, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 423D2T571U. European Medicines Agency schedules Ethinyl estradiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07277MIG. Ethinylestradiol generally arises in the molecular formula C20H24O2. The term 'ethinylestradiol' is a European Medicines Agency European Public Assessment Report System designation.

UNSPSC 51352421 Ethinyl estradiol and ethynodiol diacetate combination is a Commodity code covering a specific oral contraceptive formulation that state and local governments procure through multi-source pharmaceutical supply contracts serving health departments, correctional facilities, clinics, and employee health plans. The code sees activity primarily through state pharmacy benefit programs and cooperative purchasing alliances rather than direct single-drug solicitations, with issuing bodies including state health and human services departments, state departments of administration managing cooperative purchasing vehicles, and multi-state alliances aggregating demand across participating jurisdictions.

Recent solicitations show activity centered in Texas and Minnesota, with broader geographic reach through multi-state cooperative purchasing. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 with a March 26, 2026 response deadline, seeking manufacturers of generic multi-source pharmaceuticals and OTC products for distribution across participating state and local facilities, requiring NDC-specific pricing, cGMP and Drug Supply Chain Security Act compliance, and relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with awards effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, seeking vendor capabilities for negotiated net pricing models and value-based agreements. Neither solicitation disclosed specific award values or set-aside designations.